Mode Selection Trial (MOST) in sinus node dysfunction - MOST

Description:

The Mode Selection Trial (MOST) is a single-blind study supported by the National Heart, Lung, and Blood Institute designed to enroll 2000 patients with Sick Sinus Syndrome. All patients will receive a DDDR pacemaker programmed to VVIR or DDDR before implantation. The average time of follow-up will be 3 years. MOST has a >90% power to detect a 25% reduction in the primary end point—nonfatal stroke or total (all cause) mortality—in the DDDR-treated group. Secondary end points will inc...